Effects of Atorvastatin on Endothelial Progenitor Cells After Coronary Surgery
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01096875 |
Recruitment Status
:
Completed
First Posted
: March 31, 2010
Results First Posted
: July 9, 2014
Last Update Posted
: July 9, 2014
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Coronary Artery Bypass Surgery Elective Surgical Procedure | Drug: Atorvastatin Drug: Placebo | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 60 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Assessment of the Effects of Atorvastatin on Endothelial Progenitor Cells After Coronary ByPass Surgery; A Randomized Controlled Trial |
Study Start Date : | February 2010 |
Actual Primary Completion Date : | July 2010 |
Actual Study Completion Date : | October 2010 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Atorvastatin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
|
Drug: Atorvastatin
40mg/day once daily for two weeks prior to surgery
Other Name: Ator
|
Placebo Comparator: Placebo
Atorvastatin like pill
|
Drug: Placebo
1tb/day once daily for two weeks prior to surgery
Other Name: Placebo tablets matched to atorvastatin
|
- Endothelial Progenitor Cells (EPCs) Count (Cells/µl) [ Time Frame: Postoperative 6th hours ]
- Left Ventricular Ejection Fraction (LVEF %) Measured at 30 Days Postoperatively [ Time Frame: Change between statin and placebo groups at 30 days postoperatively ]
- High Sensitive C-reactive Protein (hsCRP mg/L) [ Time Frame: Postoperative 6th hours ]
- High Sensitive C-reactive Protein (hsCRP mg/L) [ Time Frame: 5 days postoperatively ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 30 Years to 75 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients undergoing elective isolated coronary artery bypass surgery with on-pump technique
- Written informed consent
Exclusion Criteria:
- Concomitant valve or aortic surgery
- Left ventricular aneurysm repair
- Re-operation
- Emergency surgery
- History of myocardial infarction within less than 4 weeks
- Hepatic impairment
- Chronic renal impairment
- Drug related side effects (allergy or hypersensitivity)
- Familial Hyperlipidemia
- Autoimmune conditions which require steroids

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01096875
Turkey | |
Ankara University Medical Faculty, Department of Cardiovascular Surgery | |
Ankara, Cebeci, Turkey, 06340 |
Study Director: | RUCHAN AKAR, Assoc. Prof. | Ankara University Medical Faculty, Department of Cardiovascular Surgery Ankara, Turkey, 06340 | |
Study Chair: | ONDER ASLAN, Prof. | Ankara University Medical Faculty, Department of Hematology Ankara, Turkey |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | A. Ruchan Akar, Professor, Consultant Cardiovascular Surgeon, Ankara University |
ClinicalTrials.gov Identifier: | NCT01096875 History of Changes |
Other Study ID Numbers: |
UMT0043 |
First Posted: | March 31, 2010 Key Record Dates |
Results First Posted: | July 9, 2014 |
Last Update Posted: | July 9, 2014 |
Last Verified: | July 2014 |
Keywords provided by A. Ruchan Akar, Ankara University:
Endothelial progenitor cells Atorvastatin Coronary surgery |
Additional relevant MeSH terms:
Atorvastatin Calcium Anticholesteremic Agents Hypolipidemic Agents Antimetabolites |
Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Enzyme Inhibitors |